Molecules · 2024 · 19 citations · 93 references
Life SciencesInfectious DiseasesPharmacologyMolecular PharmacologyMolecular VirologyVirologyAntiviral AgentsAntiviral PharmacologyAntiviral TherapyHost-virus InteractionsViral InfectionsViral ReplicationEconomic Burden Of DiseaseEconomic Burden Of IllnessRespiratory Viral InfectionsTreatment StrategiesViral Fusion InhibitorsViral Polymerase InhibitorsViral Replication InhibitorsViral Respiratory Infections
Respiratory syncytial virus (RSV) is a significant viral pathogen that causes respiratory infections in infants, the elderly, and immunocompromised individuals. RSV-related illnesses impose a substantial economic burden worldwide annually. The molecular structure, function, and in vivo interaction mechanisms of RSV have received more comprehensive attention in recent times, and significant progress has been made in developing inhibitors targeting various stages of the RSV replication cycle. These include fusion inhibitors, RSV polymerase inhibitors, and nucleoprotein inhibitors, as well as FDA-approved RSV prophylactic drugs palivizumab and nirsevimab. The research community is hopeful that these developments might provide easier access to knowledge and might spark new ideas for research programs.
93
Franz Bauernfeind, Gábor Horváth, Andrea Stutz et al. · The Journal of Immunology · 2009 · 2.9K citations · Full text
Coexisting Liquid Phases Underlie Nucleolar Subcompartments
Marina Feric, Nilesh Vaidya, Tyler S. Harmon et al. · Cell · 2016 · 2.1K citations · Full text
Albert Z. Kapikian, R. Mitchell, Robert M. Chanock et al. · American Journal of Epidemiology · 1969 · 1K citations